Cited by CrossRef (5)

Hamad Ghaleb Dailah, Abdullah Abdu Hommdi, Mahdi Dafer Koriri, Essa Mohammed Algathlan, Syam Mohan. Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice. Heliyon 2024;10:e24559
Francesca Romana Mauro, Potito Rosario Scalzulli, Lydia Scarfò, Carla Minoia, Roberta Murru, Paolo Sportoletti, Ferdinando Frigeri, Francesco Albano, Nicola Di Renzo, Alessandro Sanna, Luca Laurenti, Massimo Massaia, Ramona Cassin, Marta Coscia, Caterina Patti, Elsa Pennese, Agostino Tafuri, Annalisa Chiarenza, Piero Galieni, Omar Perbellini, Carmine Selleri, Catello Califano, Felicetto Ferrara, Antonio Cuneo, Marco Murineddu, Gaetano Palumbo, Ilaria Scortechini, Alessandra Tedeschi, Livio Trentin, Marzia Varettoni, Fabrizio Pane, Anna Marina Liberati, Francesco Merli, Lucia Morello, Gerardo Musuraca, Monica Tani, Adalberto Ibatici, Giulia Regazzoni, Michele Di Candia, Maria Palma, Danilo Arienti, Stefano Molica. Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study. Cancers 2024;16:1228
Emanuele Cencini, Alberto Fabbri, Donatella Raspadori, Alessandro Gozzetti, Monica Bocchia. Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?. Blood Res 2021;56:333
Rania S. Khelifi, Steven J. Huang, Kerry J. Savage, Diego Villa, David W. Scott, Khaled Ramadan, Joseph M. Connors, Laurie H. Sehn, Cynthia L. Toze, Alina S. Gerrie. Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada. Leukemia & Lymphoma 2023;64:1129
İbrahim Ethem PINAR, Vildan OZKOCAMAN. Efficacy and safety outcomes of single-agent ibrutinib therapy in chronic lymphocytic leukemia and relapsed/refractory mantle-cell lymphoma. 2023;9:1483